Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.

An Z, Aksoy O, Zheng T, Fan QW, Weiss WA

Oncogene

January 11, 2018

Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has only shown limited efficacy in patients. Here we discuss signaling pathways mediated by EGFR/EGFRvIII, current therapeutics, and novel strategies to target EGFR/EGFRvIII-amplified GBM.

Program:
CTD²
Last updated: January 31, 2018